U.S. Influenza Vaccine Market Size & Outlook, 2023-2030
U.S. influenza vaccine market, 2018-2030 (US$M)
Related Markets
U.S. influenza vaccine market highlights
- The U.S. influenza vaccine market generated a revenue of USD 3,773.4 million in 2023 and is expected to reach USD 5,770.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 3,773.4 million |
| Market revenue in 2030 | USD 5,770.8 million |
| Growth rate | 6.3% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.7% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 711.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 92.46% in 2023. Horizon Databook has segmented the U.S. influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounted for the major revenue share of the influenza vaccine market in 2022. Rapid technological advancements, recent U.S. FDA approvals for influenza vaccine, and intense competition between companies are expected to boost the market over the forecast period.
For instance, in June 2022, CSL Seqirus announced the completion of a USD 156 million expansion at its production facility in the U.S. This expansion is expected to support the formulation of its cell-based influenza vaccines in pre-filled syringes. In addition, in October 2021, Seqirus announced U.S. FDA approval of its quadrivalent influenza vaccine FLUCELVAX QUADRIVALENT.
This newly approved vaccine has an expanded age indication for children as young as 6 months old. Moreover, this product is the first and only cell-based influenza vaccine approved in the U.S. Furthermore, supportive government initiatives for vaccination and research activities are other factors propelling the country’s market.
Reasons to subscribe to U.S. influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. influenza vaccine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. influenza vaccine market size, by vaccine type, 2018-2030 (US$M)
U.S. Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
